Trial Profile

Comparison of Efficacy of PTH analogue and other therapy on the prevention of subsequent vertebral compression fracture after percutaneous vertebroplasty in patients with high risk for subsequent vertebral compression fracture: prospective comparative analysis between PTH analogue-treated group and other therapy (bisphosphonate, SERM)-treated group

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Parathyroid hormone (Primary) ; Raloxifene (Primary) ; Risedronic acid (Primary)
Indications Osteoporosis; Vertebral fracture
Focus Therapeutic Use
Acronyms SNVCF

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com